Business News • PR NewsWire • AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

NORTH CHICAGO, Ill., April 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Venclexta™ (venetoclax) tablets for patients diagnosed with chronic...

View More : http://www.prnewswire.com/news-releases/abbvie-receives-fda-accelerated-approval-of-venclexta-venetoclax-tablets-the-fir...

Releted News by prnewswire

NTT Resonant Releases "Neo Monsters" for Android OS, No.1 Paid Game for RPG Category

Fraport Traffic Figures – March and First Quarter 2016